Evidence map›Paper›PMID 33078699›Full record

ArticleThe American journal of tropical medicine and hygiene2020

The Actigraphy Sleep Score: A New Biomarker for Diagnosis, Disease Staging, and Monitoring in Human African Trypanosomiasis.

Alfred K Njamnshi, Paul F Seke Etet, Leonard Ngarka, Stephen Perrig, Gabriela C Olivera, Leonard N Nfor, Wepnyu Y Njamnshi, Alphonse Acho, Jean-Jacques Muyembe, Marina Bentivoglio and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Circadian rhythms in infectious diseases and symbiosis.Seminars in cell & developmental biology · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 6 countries.

Alfred K Njamnshi1Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon.
Paul F Seke Etet3Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon and Geneva, Switzerland.
Leonard Ngarka1Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon.
Stephen Perrig3Brain Research Africa Initiative (BRAIN), Yaoundé, Cameroon and Geneva, Switzerland.
Gabriela C Olivera6Deparment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Leonard N Nfor1Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon.
Wepnyu Y Njamnshi1Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon.
Alphonse Acho1Department of Neurology, Central Hospital Yaoundé, Yaoundé, Cameroon.
Jean-Jacques Muyembe7Institut National de la Recherche Biomédicale, Kinshasa, Democratic Republic of Congo.
Marina Bentivoglio4Department of Neurological Sciences (DSNNMM), University of Verona, Verona, Italy.
Martin Rottenberg6Deparment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Peter G E Kennedy8Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom.
Université de Yaoundé I · CMKarolinska Institutet · SEUniversity of Verona · ITNational Institute of Biomedical Research · CDUniversity Hospital of Geneva · CHUniversity of Glasgow · GB

Funding

Neural dysfunction and neuroinflammation in African brain disordersR21NS064888 · NINDS · KAROLINSKA INSTITUTE · PI KRISTENSSON, KRISTER SVEN · 2010 to 2011
$229k
NINDS NIH HHS R21 NS064888Wellcome Trust WT089992MA
6 · The paper itself

Abstract

Human African trypanosomiasis (HAT) remains a serious public health problem with diagnostic and treatment challenges in many African countries. The absence of a gold-standard biomarker has been a major difficulty for accurate disease staging and treatment follow-up. We therefore attempted to develop a simple, affordable, and noninvasive biomarker for HAT diagnosis and staging. Simultaneous actigraphy and polysomnography as well as cerebrospinal fluid (CSF) white blood cell (WBC) count, trypanosome presence, and C-X-C motif ligand (CXCL)-10 cytokine levels were performed in 20 HAT patients and nine healthy individuals (controls) using standard procedures. The International HIV Dementia Scale (IHDS) was scored in some patients as a surrogate for clinical assessment. From actigraphic parameters, we developed a novel sleep score and used it to determine correlations with other HAT markers, and compared their performance in differentiating between patients and controls and between HAT stages. The novel actigraphy sleep score (ASS) had the following ranges: 0-25 (healthy controls), 67-103 (HAT stage I), 111-126 (HAT intermediate), and 133-250 (HAT stage II). Compared with controls, stage I patients displayed a 7-fold increase in the ASS (

Indexed as

ActigraphyAdolescentAdultBiomarkersChildChild, PreschoolFemaleHumansLeukocyte CountMaleMiddle AgedSleepTrypanosoma brucei gambienseTrypanosomiasis, AfricanYoung AdultBiomarkers

Identifiers

PMID33078699
PMCPMC7695071
OpenAlexW3093421932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.